After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. resulting from allegations that ...

Asian stocks look set for a bumpy ride after renewed dip buying on Wall Street fueled a rebound in some shares, reversing a selloff triggered by a recalibration of Federal Reserve wagers.

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

At first glance, Maligaimedu in the Ariyalur district looks like any other hamlet with a few houses and a mud road flanked by empty fields on both sid.

Inscriptions on his tomb suggest that Teti Neb Fu was famous in ancient Egypt and had a number of titles. These include ...

BOSTON, MA / ACCESSWIRE / January 13, 2025 / Block & Leviton is investigating TransMedics Group, Inc. (Nasdaq:TMDX) for potential securities ...

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

Oppenheimer analysts reaffirmed Snowflake (NYSE:SNOW) as a top pick for 2025, driven by strong expectations for the company’s performance and strategic growth initiatives.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...